Factores asociados a la sobrevida en pacientescon tumor de Wilms

Introducción. El tumor de Wilms es el segundo tumor abdominal más frecuente en la edad pediátrica y responde por más del 90 % de los tumores renales en pediatría. A pesar de que la sobrevida descrita es mayor del 90 %, en nuestro medio encontramos que solo alcanza al 70 %, por lo que deseamos evalua...

Full description

Autores:
Herrera Toro, Mirian Natalia
Peña Aguirre, Laura
Molina Castaño, Carlos Federico
Tipo de recurso:
Article of investigation
Fecha de publicación:
2020
Institución:
Tecnológico de Antioquia
Repositorio:
Repositorio Tdea
Idioma:
spa
OAI Identifier:
oai:dspace.tdea.edu.co:tdea/3836
Acceso en línea:
https://dspace.tdea.edu.co/handle/tdea/3836
Palabra clave:
Tumor de Wilms
Wilms Tumor
Tumeur de Wilms
Nefroblastoma
Nephroblastoma
Néphroblastome
Cirugía
Surgery
Chirurgie
Urología
Urology
Urologie
Oncología Quirúrgica
Surgical Oncology
Oncologia Cirúrgica
Oncologie chirurgicale
Supervivientes de Cáncer
Cancer Survivors
Sobreviventes de Câncer
Survivants du cancer
Pediatría
Pediatrics
Pédiatrie
Quimioterapia
Drug Therapy
Tratamento Farmacológico
Traitement médicamenteux
Rights
openAccess
License
https://creativecommons.org/licenses/by-nc-nd/4.0/
id RepoTdea2_6f5ac440c8c48509cf81cd7fa48cd841
oai_identifier_str oai:dspace.tdea.edu.co:tdea/3836
network_acronym_str RepoTdea2
network_name_str Repositorio Tdea
repository_id_str
dc.title.none.fl_str_mv Factores asociados a la sobrevida en pacientescon tumor de Wilms
dc.title.translated.none.fl_str_mv Factors associated with survival in patient with Wilms tumor
title Factores asociados a la sobrevida en pacientescon tumor de Wilms
spellingShingle Factores asociados a la sobrevida en pacientescon tumor de Wilms
Tumor de Wilms
Wilms Tumor
Tumeur de Wilms
Nefroblastoma
Nephroblastoma
Néphroblastome
Cirugía
Surgery
Chirurgie
Urología
Urology
Urologie
Oncología Quirúrgica
Surgical Oncology
Oncologia Cirúrgica
Oncologie chirurgicale
Supervivientes de Cáncer
Cancer Survivors
Sobreviventes de Câncer
Survivants du cancer
Pediatría
Pediatrics
Pédiatrie
Quimioterapia
Drug Therapy
Tratamento Farmacológico
Traitement médicamenteux
title_short Factores asociados a la sobrevida en pacientescon tumor de Wilms
title_full Factores asociados a la sobrevida en pacientescon tumor de Wilms
title_fullStr Factores asociados a la sobrevida en pacientescon tumor de Wilms
title_full_unstemmed Factores asociados a la sobrevida en pacientescon tumor de Wilms
title_sort Factores asociados a la sobrevida en pacientescon tumor de Wilms
dc.creator.fl_str_mv Herrera Toro, Mirian Natalia
Peña Aguirre, Laura
Molina Castaño, Carlos Federico
dc.contributor.author.none.fl_str_mv Herrera Toro, Mirian Natalia
Peña Aguirre, Laura
Molina Castaño, Carlos Federico
dc.subject.decs.none.fl_str_mv Tumor de Wilms
Wilms Tumor
Tumeur de Wilms
Nefroblastoma
Nephroblastoma
Néphroblastome
Cirugía
Surgery
Chirurgie
Urología
Urology
Urologie
Oncología Quirúrgica
Surgical Oncology
Oncologia Cirúrgica
Oncologie chirurgicale
Supervivientes de Cáncer
Cancer Survivors
Sobreviventes de Câncer
Survivants du cancer
Pediatría
Pediatrics
Pédiatrie
Quimioterapia
Drug Therapy
Tratamento Farmacológico
Traitement médicamenteux
topic Tumor de Wilms
Wilms Tumor
Tumeur de Wilms
Nefroblastoma
Nephroblastoma
Néphroblastome
Cirugía
Surgery
Chirurgie
Urología
Urology
Urologie
Oncología Quirúrgica
Surgical Oncology
Oncologia Cirúrgica
Oncologie chirurgicale
Supervivientes de Cáncer
Cancer Survivors
Sobreviventes de Câncer
Survivants du cancer
Pediatría
Pediatrics
Pédiatrie
Quimioterapia
Drug Therapy
Tratamento Farmacológico
Traitement médicamenteux
description Introducción. El tumor de Wilms es el segundo tumor abdominal más frecuente en la edad pediátrica y responde por más del 90 % de los tumores renales en pediatría. A pesar de que la sobrevida descrita es mayor del 90 %, en nuestro medio encontramos que solo alcanza al 70 %, por lo que deseamos evaluar cuáles son los factores asociados con dichos resultados desfavorables, con el fin de implementar medidas para mejorar la sobrevida de nuestros pacientes.Métodos. Se realizó un estudio observacional, transversal, en dos centros de alto nivel de atención, que incluyó una muestra de 84 pacientes menores de 15 años, con diagnóstico de tumor de Wilms.Resultados. Los factores que se asociaron significativamente con un aumento en la probabilidad de morir fueron: no completar el protocolo de quimioterapia, (OR 34; IC95% 3,7-312; p 0,000) y presentar recidiva tumoral (OR 35,7; IC95% 6,9-184; p 0,000). Otros factores que aumentaron esta probabilidad sin alcanzar a ser significativos, pero mostrando una evidente tendencia fueron: presentación bilateral (OR 4,1; IC95% 0,6-5,5; p 0,147), complicaciones quirúrgicas (OR 3,2; IC95% 0,7-14,6; p 0,136), compromiso de ganglios linfáticos en tomografía (OR 2,4; IC95% 0,7-8,4; p 0,139) y las metástasis a distancia (OR 2,5; IC95% 0,7-9; p 0,143). Discusión. La sobrevida de nuestros niños con tumor de Wilms es menor que la reportada en la literatura mundial, siendo la falla en terminar la quimioterapia, la recidiva y la necesidad de cirugía bilateral, los factores asociados con este desenlace. Palabras clave: tumor de Wilms; nefroblastoma; cirugía; urología; oncología quirúrgica; supervivientes de cáncer.
publishDate 2020
dc.date.issued.none.fl_str_mv 2020
dc.date.accessioned.none.fl_str_mv 2023-09-02T23:10:25Z
dc.date.available.none.fl_str_mv 2023-09-02T23:10:25Z
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
format http://purl.org/coar/resource_type/c_2df8fbb1
status_str publishedVersion
dc.identifier.issn.spa.fl_str_mv 2011-7582
dc.identifier.uri.none.fl_str_mv https://dspace.tdea.edu.co/handle/tdea/3836
dc.identifier.eissn.spa.fl_str_mv 2619-6107
identifier_str_mv 2011-7582
2619-6107
url https://dspace.tdea.edu.co/handle/tdea/3836
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.citationendpage.spa.fl_str_mv 629
dc.relation.citationissue.spa.fl_str_mv 4
dc.relation.citationstartpage.spa.fl_str_mv 621
dc.relation.citationvolume.spa.fl_str_mv 35
dc.relation.ispartofjournal.spa.fl_str_mv Revista Colombiana de Cirugía
dc.relation.references.spa.fl_str_mv Mejía F. Tumor de Wilms (nefroblastoma). En: Arango-Rave ME, Herrera-Toro N, Uribe-Restrepo FL, editores. Cirugía Pediátrica. Segunda edición. Medellín: Editorial Universidad de Antioquia, 2017. p 365-371.
Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the UnitedStates. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995;75:2186-95. https://doi.org/10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F
Stiller CA, Parkin DM. International variations in the incidence of childhood renal tumours. Br J Cancer. 1990;62:1026-30. https://doi.org/10.1038/bjc.1990.432
Instituto Nacional de Cancerología - ESE. Anuario Estadístico 2015. Bogotá, 2018. p. 120. Fecha de consulta: 20 de enero de 2020. Disponible en: http://www.cancer.gov.co/files/libros/archivos/2015
Herrera-Toro NH, Peña-Aguirre L, Arango-Rave ME. Tumor de Wilms: experiencia de 12 años en dos hospitales de alto nivel en Medellín, Colombia. Iatreia. 2019;32:82-91. https://doi.org/10.17533/udea.iatreia.13
D’Angelo P, Di Cataldo A, Terenziani M, Bisogno G, Collini P, Di Martino M, et al. Factors possibly affecting prognosis in children with Wilms’ tumor diagnosed before 24 months of age: A report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Wilms Tumor WorkingGroup. Pediatr Blood Cancer. 2017;64:12-64. https://doi.org/10.1002/pbc.26644
Aronson DC, Hadley GP. Age is not a prognostic factor in children with Wilms tumor beyond stage I in Africa. Pediatr Blood Cancer. 2014;61:987-9. https://doi.org/10.1002/pbc.24948
Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral non metastatic Wilms tumor. Klin Padiatr. 2004;216:132-40. https://doi.org/10.1055/s-2004-822625
Dome JS, Perlman EJ, Graf N. Risk stratification for Wilms tumor: current approach and future directions. Am Soc Clin Oncol. 2014;34:215-23. https://doi.org/10.14694/EdBook_AM.2014.34.215
Uba AF, Chirdan LB. Childhood Wilms’ tumour: prognostic factors in North Central Nigeria. West Afr J Med. 2007;26:222-5. https://doi.org/10.4314/wajm.v26i3.28314
Ekenze SO, Agugua-Obianyo NEN, Odetunde OA. The challenge of nephroblastoma in a developing country. Ann Oncol. 2006;17:1598-1600. https://doi.org/10.1093/annonc/mdl167
Axt J, Abdallah F, Axt M, Githanga J, Hansen E, Lessan J, et al. Wilms tumor survival in Kenya. J Pediatr Surg. 2013;48:1254-62. https://doi.org/10.1016/j.jpedsurg.2013.03.021
Atanda AT, Anyanwu L-JC, Atanda OJ, Mohammad AM, Abdullahi LB, Farinyaro AU. Wilms’ tumour: Determinants of prognosis in an African setting. Afr J Paediatr Surg. 2015;12:171-6. https://doi.org/10.4103/0189-6725.170185
Abubakar AM, Bwala JK, Abdur-Rahman LO, Chinda JY, Adeniran JO. Outcome of treatment of nephroblastoma in Nigerian children. Afr J Paediatr Surg. 2010;7:45-52.
Osuoji RI, Williams OM, Ajai OT, Idika OC, Abolarinwa AA, Bankole MA. Wilms’ tumour: Experience in a developing tertiary centre in Nigeria. East Cent Afr J Surg. 2011;16:123-8.
Sangkhathat S, Chotsampancharaen T, Kayasut K, Patrapinyokul S, Chiengkriwate P, Kitichet R, et al. Outcomes of pediatric nephroblastoma in southern Thailand. Asian Pac J Cancer Prev. 2008;9:643-7.
Saltzman AF, Carrasco A, Amini A, Aldrink JH, Dasgupta R, Gow KW, et al. Patterns of lymph node sampling and the impact of lymph node density in favorable histology Wilms tumor: An analysis of the national cancer database. J Pediatr Urol. 2018;14:161.e1–161.e8. https://doi.org/10.1016/j.jpurol.2017.09.025
Zhuge Y, Cheung MC, Yang R, Koniaris LG, Neville HL, Sola JE. Improved survival with lymph node sampling in Wilms tumor. J Surg Res. 2011;167:e199-203. https://doi.org/10.1016/j.jss.2010.12.026
Kutluk T, Varan A, Büyükpamukçu N, Atahan L, Cağlar M, Akyüz C, et al. Improved survival of children with Wilms tumor. J Pediatr Hematol Oncol. 2006;28:423-6.
Breslow N, Sharples K, Beckwith JB, Takashima J, Kelalis PP, Green DM, et al. Prognostic factors in non metastatic, favorable histology Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer. 1991;68:2345-53. https://doi.org/10.1002/1097-0142(19911201)68:11<2345::aid-cncr2820681103>3.0.co;2-t
Fernandez CV, Mullen EA, Chi Y-Y, Ehrlich PF, Perlman EJ, Kalapurakal JA, et al. Outcome and prognostic factors in stage III favorable-histology Wilms tumor: A report from the Children’s Oncology Group Study AREN0532. J Clin Oncol. 2018;36:254-61. https://doi.org/10.1200/JCO.2017.73.7999
Kinoshita Y, Suminoe A, Inada H, Yagi M, Yanai F, Zaizen Y, et al. The prognostic significance of blastemal predominant histology in initially resected Wilms’ tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan. J Pediatr Surg. 2012;47:2205-9. https://doi.org/10.1016/j.jpedsurg.2012.09.009
Aoba T, Urushihara N, Fukumoto K, Furuta S, Fukuzawa H, Mitsunaga M, et al. Relapse of unilateral favorable histology Wilms’ tumor: significant clinicopathological factors. J Pediatr Surg. 2012;47:2210-15. https://doi.org/10.1016/j.jpedsurg.2012.09.010
Vujanić GM, Gessler M, Ooms AHAG, Collini P, Coulomb-l’Hermine A, D’Hooghe E, et al. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol. 2018;15:693-701. https://doi.org/10.1038/s41585-018-0100-3
Zani A, Schiavetti A, Gambino M, Cozzi DA, Conforti A, Cozzi F. Long-term outcome of nephron sparing surgery and simple nephrectomy for unilateral localized Wilms tumor. J Urol. 2005;173:946-8. https://doi.org/10.1097/01.ju.0000152580.90861.d3
Sarhan OM, El-Baz M, Sarhan MM, Ghali AM, Ghoneim MA. Bilateral Wilms’ tumors: single-center experience with 22 cases and literature review. Urology. 2010;76:946-51. https://doi.org/10.1016/j.urology.2010.03.055
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.license.spa.fl_str_mv Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 9 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.coverage.city.none.fl_str_mv Medellín, Colombia
dc.publisher.spa.fl_str_mv Asociación Colombiana de Cirugía
dc.publisher.place.spa.fl_str_mv Colombia
dc.source.spa.fl_str_mv https://www.revistacirugia.org/index.php/cirugia/article/view/556
institution Tecnológico de Antioquia
bitstream.url.fl_str_mv https://dspace.tdea.edu.co/bitstream/tdea/3836/4/Factores%20asociados%20a%20la%20sobrevida%20en%20pacientes%20con%20tumor%20de%20Wilms.pdf.jpg
https://dspace.tdea.edu.co/bitstream/tdea/3836/3/Factores%20asociados%20a%20la%20sobrevida%20en%20pacientes%20con%20tumor%20de%20Wilms.pdf.txt
https://dspace.tdea.edu.co/bitstream/tdea/3836/2/license.txt
https://dspace.tdea.edu.co/bitstream/tdea/3836/1/Factores%20asociados%20a%20la%20sobrevida%20en%20pacientes%20con%20tumor%20de%20Wilms.pdf
bitstream.checksum.fl_str_mv a2e7ebcefa0d26a92431249031e99d3f
3a8fdb4fb19a068a898ca467fedebcdd
2f9959eaf5b71fae44bbf9ec84150c7a
c79029a6fddf4b380b42ff44a8c763fb
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Tecnologico de Antioquia
repository.mail.fl_str_mv bdigital@metabiblioteca.com
_version_ 1812189285341724672
spelling Herrera Toro, Mirian Nataliad7295771-d228-4e0c-b68e-5532093afcd4Peña Aguirre, Laura20ce4f5b-fa3e-4f99-917e-8b15e9467708Molina Castaño, Carlos Federico0bc3477d-f51c-460a-8587-5015dbb715ec2023-09-02T23:10:25Z2023-09-02T23:10:25Z20202011-7582https://dspace.tdea.edu.co/handle/tdea/38362619-6107Introducción. El tumor de Wilms es el segundo tumor abdominal más frecuente en la edad pediátrica y responde por más del 90 % de los tumores renales en pediatría. A pesar de que la sobrevida descrita es mayor del 90 %, en nuestro medio encontramos que solo alcanza al 70 %, por lo que deseamos evaluar cuáles son los factores asociados con dichos resultados desfavorables, con el fin de implementar medidas para mejorar la sobrevida de nuestros pacientes.Métodos. Se realizó un estudio observacional, transversal, en dos centros de alto nivel de atención, que incluyó una muestra de 84 pacientes menores de 15 años, con diagnóstico de tumor de Wilms.Resultados. Los factores que se asociaron significativamente con un aumento en la probabilidad de morir fueron: no completar el protocolo de quimioterapia, (OR 34; IC95% 3,7-312; p 0,000) y presentar recidiva tumoral (OR 35,7; IC95% 6,9-184; p 0,000). Otros factores que aumentaron esta probabilidad sin alcanzar a ser significativos, pero mostrando una evidente tendencia fueron: presentación bilateral (OR 4,1; IC95% 0,6-5,5; p 0,147), complicaciones quirúrgicas (OR 3,2; IC95% 0,7-14,6; p 0,136), compromiso de ganglios linfáticos en tomografía (OR 2,4; IC95% 0,7-8,4; p 0,139) y las metástasis a distancia (OR 2,5; IC95% 0,7-9; p 0,143). Discusión. La sobrevida de nuestros niños con tumor de Wilms es menor que la reportada en la literatura mundial, siendo la falla en terminar la quimioterapia, la recidiva y la necesidad de cirugía bilateral, los factores asociados con este desenlace. Palabras clave: tumor de Wilms; nefroblastoma; cirugía; urología; oncología quirúrgica; supervivientes de cáncer.Introduction. Wilms tumor is the second most frequent abdominal tumor in pediatric age, and it accounts for more than 90% of kidney tumors in pediatrics. Although the described survival is greater than 90%, in our set-ting we find that it only reaches 70%. Our objective was to evaluate the factors associated with these unfavorable results, in order to implement measures to improve the survival of our patients.Methods. An observational, cross-sectional study was conducted in two tertiary medical centers, which included a sample of 84 patients under 15 years of age with a diagnosis of Wilms tumor.Results. The factors that were significantly associated with an increase in the probability of dying were not com-pleting the chemotherapy protocol (OR 34; 95%CI 3.7-312; p 0.000) and presenting tumor recurrence (OR 35.7; 95%CI 6.9-184; p 0.000). Other factors that increased this probability without being significant, but showing an evident trend were: bilateral presentation (OR 4.1; 95%CI 0.6-5.5; p 0.147), surgical complications (OR 3.2; 95%CI 0.7-14.6; p 0.136), lymph node involvement in tomography (OR 2.4; 95%CI 0.7-8.4; p 0.139) and distant metastases (OR 2.5; 95%CI 0.7-9; p 0.143).Discussion. The survival of the children with Wilms tumor in our study was lower than that reported in the world literature, with failure to complete chemotherapy, recurrence and the need for bilateral surgery being the factors associated with this outcome.Keywords:Wilms tumor; nephroblastoma; surgery; urology; surgical oncology; cancer survivors.9 páginasapplication/pdfspaAsociación Colombiana de CirugíaColombiahttps://creativecommons.org/licenses/by-nc-nd/4.0/Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2https://www.revistacirugia.org/index.php/cirugia/article/view/556Factores asociados a la sobrevida en pacientescon tumor de WilmsFactors associated with survival in patient with Wilms tumorArtículo de revistahttp://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Medellín, Colombia629462135Revista Colombiana de CirugíaMejía F. Tumor de Wilms (nefroblastoma). En: Arango-Rave ME, Herrera-Toro N, Uribe-Restrepo FL, editores. Cirugía Pediátrica. Segunda edición. Medellín: Editorial Universidad de Antioquia, 2017. p 365-371.Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the UnitedStates. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer. 1995;75:2186-95. https://doi.org/10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-FStiller CA, Parkin DM. International variations in the incidence of childhood renal tumours. Br J Cancer. 1990;62:1026-30. https://doi.org/10.1038/bjc.1990.432Instituto Nacional de Cancerología - ESE. Anuario Estadístico 2015. Bogotá, 2018. p. 120. Fecha de consulta: 20 de enero de 2020. Disponible en: http://www.cancer.gov.co/files/libros/archivos/2015Herrera-Toro NH, Peña-Aguirre L, Arango-Rave ME. Tumor de Wilms: experiencia de 12 años en dos hospitales de alto nivel en Medellín, Colombia. Iatreia. 2019;32:82-91. https://doi.org/10.17533/udea.iatreia.13D’Angelo P, Di Cataldo A, Terenziani M, Bisogno G, Collini P, Di Martino M, et al. Factors possibly affecting prognosis in children with Wilms’ tumor diagnosed before 24 months of age: A report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) Wilms Tumor WorkingGroup. Pediatr Blood Cancer. 2017;64:12-64. https://doi.org/10.1002/pbc.26644Aronson DC, Hadley GP. Age is not a prognostic factor in children with Wilms tumor beyond stage I in Africa. Pediatr Blood Cancer. 2014;61:987-9. https://doi.org/10.1002/pbc.24948Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral non metastatic Wilms tumor. Klin Padiatr. 2004;216:132-40. https://doi.org/10.1055/s-2004-822625Dome JS, Perlman EJ, Graf N. Risk stratification for Wilms tumor: current approach and future directions. Am Soc Clin Oncol. 2014;34:215-23. https://doi.org/10.14694/EdBook_AM.2014.34.215Uba AF, Chirdan LB. Childhood Wilms’ tumour: prognostic factors in North Central Nigeria. West Afr J Med. 2007;26:222-5. https://doi.org/10.4314/wajm.v26i3.28314Ekenze SO, Agugua-Obianyo NEN, Odetunde OA. The challenge of nephroblastoma in a developing country. Ann Oncol. 2006;17:1598-1600. https://doi.org/10.1093/annonc/mdl167Axt J, Abdallah F, Axt M, Githanga J, Hansen E, Lessan J, et al. Wilms tumor survival in Kenya. J Pediatr Surg. 2013;48:1254-62. https://doi.org/10.1016/j.jpedsurg.2013.03.021Atanda AT, Anyanwu L-JC, Atanda OJ, Mohammad AM, Abdullahi LB, Farinyaro AU. Wilms’ tumour: Determinants of prognosis in an African setting. Afr J Paediatr Surg. 2015;12:171-6. https://doi.org/10.4103/0189-6725.170185Abubakar AM, Bwala JK, Abdur-Rahman LO, Chinda JY, Adeniran JO. Outcome of treatment of nephroblastoma in Nigerian children. Afr J Paediatr Surg. 2010;7:45-52.Osuoji RI, Williams OM, Ajai OT, Idika OC, Abolarinwa AA, Bankole MA. Wilms’ tumour: Experience in a developing tertiary centre in Nigeria. East Cent Afr J Surg. 2011;16:123-8.Sangkhathat S, Chotsampancharaen T, Kayasut K, Patrapinyokul S, Chiengkriwate P, Kitichet R, et al. Outcomes of pediatric nephroblastoma in southern Thailand. Asian Pac J Cancer Prev. 2008;9:643-7.Saltzman AF, Carrasco A, Amini A, Aldrink JH, Dasgupta R, Gow KW, et al. Patterns of lymph node sampling and the impact of lymph node density in favorable histology Wilms tumor: An analysis of the national cancer database. J Pediatr Urol. 2018;14:161.e1–161.e8. https://doi.org/10.1016/j.jpurol.2017.09.025Zhuge Y, Cheung MC, Yang R, Koniaris LG, Neville HL, Sola JE. Improved survival with lymph node sampling in Wilms tumor. J Surg Res. 2011;167:e199-203. https://doi.org/10.1016/j.jss.2010.12.026Kutluk T, Varan A, Büyükpamukçu N, Atahan L, Cağlar M, Akyüz C, et al. Improved survival of children with Wilms tumor. J Pediatr Hematol Oncol. 2006;28:423-6.Breslow N, Sharples K, Beckwith JB, Takashima J, Kelalis PP, Green DM, et al. Prognostic factors in non metastatic, favorable histology Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer. 1991;68:2345-53. https://doi.org/10.1002/1097-0142(19911201)68:11<2345::aid-cncr2820681103>3.0.co;2-tFernandez CV, Mullen EA, Chi Y-Y, Ehrlich PF, Perlman EJ, Kalapurakal JA, et al. Outcome and prognostic factors in stage III favorable-histology Wilms tumor: A report from the Children’s Oncology Group Study AREN0532. J Clin Oncol. 2018;36:254-61. https://doi.org/10.1200/JCO.2017.73.7999Kinoshita Y, Suminoe A, Inada H, Yagi M, Yanai F, Zaizen Y, et al. The prognostic significance of blastemal predominant histology in initially resected Wilms’ tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan. J Pediatr Surg. 2012;47:2205-9. https://doi.org/10.1016/j.jpedsurg.2012.09.009Aoba T, Urushihara N, Fukumoto K, Furuta S, Fukuzawa H, Mitsunaga M, et al. Relapse of unilateral favorable histology Wilms’ tumor: significant clinicopathological factors. J Pediatr Surg. 2012;47:2210-15. https://doi.org/10.1016/j.jpedsurg.2012.09.010Vujanić GM, Gessler M, Ooms AHAG, Collini P, Coulomb-l’Hermine A, D’Hooghe E, et al. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol. 2018;15:693-701. https://doi.org/10.1038/s41585-018-0100-3Zani A, Schiavetti A, Gambino M, Cozzi DA, Conforti A, Cozzi F. Long-term outcome of nephron sparing surgery and simple nephrectomy for unilateral localized Wilms tumor. J Urol. 2005;173:946-8. https://doi.org/10.1097/01.ju.0000152580.90861.d3Sarhan OM, El-Baz M, Sarhan MM, Ghali AM, Ghoneim MA. Bilateral Wilms’ tumors: single-center experience with 22 cases and literature review. Urology. 2010;76:946-51. https://doi.org/10.1016/j.urology.2010.03.055Tumor de WilmsWilms TumorTumeur de WilmsNefroblastomaNephroblastomaNéphroblastomeCirugíaSurgeryChirurgieUrologíaUrologyUrologieOncología QuirúrgicaSurgical OncologyOncologia CirúrgicaOncologie chirurgicaleSupervivientes de CáncerCancer SurvivorsSobreviventes de CâncerSurvivants du cancerPediatríaPediatricsPédiatrieQuimioterapiaDrug TherapyTratamento FarmacológicoTraitement médicamenteuxTHUMBNAILFactores asociados a la sobrevida en pacientes con tumor de Wilms.pdf.jpgFactores asociados a la sobrevida en pacientes con tumor de Wilms.pdf.jpgGenerated Thumbnailimage/jpeg12363https://dspace.tdea.edu.co/bitstream/tdea/3836/4/Factores%20asociados%20a%20la%20sobrevida%20en%20pacientes%20con%20tumor%20de%20Wilms.pdf.jpga2e7ebcefa0d26a92431249031e99d3fMD54open accessTEXTFactores asociados a la sobrevida en pacientes con tumor de Wilms.pdf.txtFactores asociados a la sobrevida en pacientes con tumor de Wilms.pdf.txtExtracted texttext/plain31166https://dspace.tdea.edu.co/bitstream/tdea/3836/3/Factores%20asociados%20a%20la%20sobrevida%20en%20pacientes%20con%20tumor%20de%20Wilms.pdf.txt3a8fdb4fb19a068a898ca467fedebcddMD53open accessLICENSElicense.txtlicense.txttext/plain; charset=utf-814828https://dspace.tdea.edu.co/bitstream/tdea/3836/2/license.txt2f9959eaf5b71fae44bbf9ec84150c7aMD52open accessORIGINALFactores asociados a la sobrevida en pacientes con tumor de Wilms.pdfFactores asociados a la sobrevida en pacientes con tumor de Wilms.pdfapplication/pdf329703https://dspace.tdea.edu.co/bitstream/tdea/3836/1/Factores%20asociados%20a%20la%20sobrevida%20en%20pacientes%20con%20tumor%20de%20Wilms.pdfc79029a6fddf4b380b42ff44a8c763fbMD51open accesstdea/3836oai:dspace.tdea.edu.co:tdea/38362023-09-03 03:03:10.868An error occurred on the license name.|||https://creativecommons.org/licenses/by-nc-nd/4.0/open accessRepositorio Institucional Tecnologico de Antioquiabdigital@metabiblioteca.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